EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Gout and diabetic retinopathy: elevated risks and the protective role of urate-lowering therapy

Ahmed Abdi, Ahmed M Alshaikhsalama, Angeline L Wang

Graefe's Archive for Clinical and Experimental Ophthalmology · 05.08.2026

DOI: 10.1007/s00417-026-07438-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, online erschienen am 05.08.2026. Verfasst von Ahmed Abdi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390, USA. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research to Prevent Blindness.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To assess the risk of diabetic retinopathy (DR), vision-threatening complications (VTCs), and ocular interventions in patients with diabetes stratified by gout status, and to evaluate the potential protective effect of urate-lowering therapy (ULT).

Methods

This retrospective cohort study utilized the TriNetX Health Research Network. Patients with type 2 diabetes mellitus were identified using ICD-10 codes and stratified by the presence or absence of gout. Patients with less than one year of follow-up, pre-existing DR, or confounding ocular conditions were excluded. Propensity score matching was performed for demographics, systemic comorbidities, body mass index, and medications. Primary outcomes included the development of nonproliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), vitreous hemorrhage (VH), diabetic macular edema (DME), tractional retinal detachment (TRD), neovascular glaucoma (NVG), and the need for intravitreal injections (IVI), panretinal photocoagulation (PRP), and pars plana vitrectomy (PPV) at one, three, and five years. A secondary analysis evaluated gout patients with severe NPDR or PDR stratified by ULT use.

Results

After matching, 21,707 patients were analyzed in each cohort. The gout cohort had significantly higher risks of NPDR (RR: 8.31, 95% CI: 6.25–11.36, p < .0001), PDR (RR: 1.75, 95% CI: 1.22–2.41, p = .0015), VH (RR: 5.83, 95% CI: 3.79–8.99, p < .0001), DME (RR: 6.94, 95% CI: 4.96–9.71, p < .0001), and NVG (RR: 3.90, 95% CI: 2.35–6.45, p < .0001) at five years. The gout cohort also required more IVI (RR: 2.88, 95% CI: 2.21–3.75, p < .0001), PRP (RR: 7.60, 95% CI: 3.93–14.69, p < .0001), and PPV (RR: 4.00, 95% CI: 2.00–8.00, p < .0001). In the secondary analysis (3,425 patients per cohort), ULT was associated with lower risks of VH (RR: 0.59, 95% CI: 0.42–0.84, p = .0025), DME (RR: 0.81, 95% CI: 0.70–0.94, p = .0045), PPV (RR: 0.44, 95% CI: 0.21–0.91, p = .02), and IVI (RR: 0.78, 95% CI: 0.58–0.98, p =.02). No significant differences were observed for TRD in either analysis.

Conclusion

Gout in patients with diabetes is associated with significantly higher risks of DR, VTCs, and need for ocular interventions. ULT may reduce VTC risk and the need for certain interventions. Prospective trials are needed to confirm these findings. Key messages What is known Hyperuricemia and gout are linked to increased oxidative stress and endothelial dysfunction, and upregulation of inflammatory mediators and VEGF pathways implicated in the development and progression of diabetic retinopathy. Large-scale evidence on the association between clinically diagnosed gout and diabetic retinopathy outcomes remains limited. What is new Patients with T2DM and gout had significantly elevated 5-year risks of NPDR and PDR, VH, DME, NVG, and a greater need for intravitreal injections, PRP, and PPV compared to matched controls. Among gout patients with established DR, urate-lowering therapy was associated with significantly reduced risks of VH, DME, and the need for intravitreal injections and PPV. These findings suggest a potential protective role for urate-lowering therapy in vision-threatening complications of DR, warranting prospective investigation.

Schlagwörter

Stichwörter der Autor:innen

Diabetic retinopathyGoutPanretinal photocoagulationUrate-lowering therapy

Autor:innen und Institutionen

  • Department of Ophthalmology, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390, USA.
  • Department of Ophthalmology, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390, USA. angeline.wang@utsouthwestern.edu.

Förderung

  • Research to Prevent Blindness

Zitieren

APA

Abdi, A., Alshaikhsalama, A. M., & Wang, A. L. (2026). Gout and diabetic retinopathy: elevated risks and the protective role of urate-lowering therapy. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-026-07438-3

Vancouver

Abdi A, Alshaikhsalama AM, Wang AL. Gout and diabetic retinopathy: elevated risks and the protective role of urate-lowering therapy. Graefe's Archive for Clinical and Experimental Ophthalmology. 2026. doi:10.1007/s00417-026-07438-3

BibTeX
@article{Abdi2026,
  author = {Abdi, Ahmed and Alshaikhsalama, Ahmed M and Wang, Angeline L},
  title = {Gout and diabetic retinopathy: elevated risks and the protective role of urate-lowering therapy},
  journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
  year = {2026},
  doi = {10.1007/s00417-026-07438-3}
}
Kostenlos starten →